INHALED IMATINIB FOR PULMONARY ARTERIAL HYPERTENSION CLINICAL TRIAL: DESIGN OF THE IMPACT PHASE 2B/3 STUDY DESIGN

被引：1
|
作者：
Gillies, Hunter
Chakinala, Murali M.
Dake, Ben
Feldman, Jeremy P.
Hoeper, Marius M.
Humbert, Marc
Jing, Zhi-Cheng
Langley, Jonathan
McLaughlin, Vallerie
Niven, Ralph
Rosenkranz, Stephan H.
Zhang, Xiaosha
Hill, Nicholas S.
机构：
来源：
CHEST | 2022年 / 162卷 / 04期
关键词：
D O I：
10.1016/j.chest.2022.08.1923
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：2325A / 2329A
页数：5
相关论文
共 50 条
  • [21] MECHANISTIC MODELLING TO OPTIMIZE PHASE 2b CLINICAL TRIAL DESIGN OF A NEW COMBINATION THERAPY FOR CHRONIC HBV
    Granjeon-Noriot, Solene
    Peyronnet, Emmanuel
    Schneider, Anne
    Courcelles, Eulalie
    Martin, Bastien
    Arsene, Simon
    Darre, Hippolyte
    Jacob, Evgueni
    Kahoul, Riad
    Girma, Hugo
    Odoul, Marion
    Martin, Isabelle
    Meyniel-Schicklin, Laurene
    Scalfaro, Pietro
    Illigens, Ben
    Brueziere, Lara
    HEPATOLOGY, 2021, 74 : 511A - 511A
  • [22] HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension
    Li, Ying
    Li, Xiao-hui
    Yu, Zai-xin
    Cai, Jing-jing
    Billiar, Timothy R.
    Chen, Alex F.
    Lv, Ben
    Chen, Zi-ying
    Huang, Zhi-jun
    Yang, Guo-ping
    Song, Jie
    Liu, Bin
    Yuan, Hong
    PULMONARY CIRCULATION, 2015, 5 (03) : 538 - 546
  • [23] TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
    Frantz, Robert P.
    Benza, Raymond L.
    Channick, Richard N.
    Chin, Kelly
    Howard, Luke S.
    McLaughlin, Vallerie V.
    Sitbon, Olivier
    Zamanian, Roham T.
    Hemnes, Anna R.
    Cravets, Matt
    Bruey, Jean-Marie
    Roscigno, Robert
    Mottola, David
    Elman, Erin
    Zisman, Lawrence S.
    Ghofrani, Hossein-Ardeschir
    PULMONARY CIRCULATION, 2021, 11 (04)
  • [24] Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension A Randomized Controlled Clinical Trial
    McLaughlin, Vallerie V.
    Benza, Raymond L.
    Rubin, Lewis J.
    Channick, Richard N.
    Voswinckel, Robert
    Tapson, Victor F.
    Robbins, Ivan M.
    Olschewski, Horst
    Rubenfire, Melvyn
    Seeger, Werner
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (18) : 1915 - 1922
  • [25] Study Design Of The Motion Trial: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not On Active Treatment
    Mathai, S. C.
    Minai, O. A.
    Sullivan, S.
    Lerner, D.
    Levine, D.
    Platt, D.
    Joish, V. N.
    Satler, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [26] Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension
    West, James D.
    Carrier, Erica J.
    Bloodworth, Nathaniel C.
    Schroer, Alison K.
    Chen, Peter
    Ryzhova, Larisa M.
    Gladson, Santhi
    Shay, Sheila
    Hutcheson, Joshua D.
    Merryman, W. David
    PLOS ONE, 2016, 11 (02):
  • [27] End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
    Peacock, A. J.
    Naeije, R.
    Galie, N.
    Rubin, L.
    EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (01) : 231 - 242
  • [28] Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy
    Wilkins, Martin R.
    Mckie, Mikel A.
    Law, Martin
    Roussakis, Andreas A.
    Harbaum, Lars
    Church, Colin
    Coghlan, J. Gerry
    Condliffe, Robin
    Howard, Luke S.
    Kiely, David G.
    Lordan, Jim
    Rothman, Alexander
    Suntharalingam, Jay
    Toshner, Mark
    Wort, Stephen J.
    Villar, Sofia S.
    PULMONARY CIRCULATION, 2021, 11 (04)
  • [29] RATIONALE AND DESIGN OF THE PRIMEX TRIAL: A STUDY OF 2 DOSES OF ORAL CXA-10 IN PULMONARY ARTERIAL HYPERTENSION (PAH)
    Simon, Marc
    Machado, Roberto
    Badesch, David
    Benza, Raymond
    Simon, J.
    Mardi, Gibbs
    Anna, Gomberg-Maitland
    Steven, Hemnes
    Ronald, Kawut
    Theodore, Oudiz
    Gerald, Danoff
    Brien, O.
    Gladwin, Mark
    CHEST, 2020, 158 (04) : 2246A - 2248A
  • [30] CS1, a controlled-release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial
    Benza, Raymond L.
    Adamson, Philip B.
    Bhatt, Deepak L.
    Frick, Fredrik
    Olsson, Gunnar
    Bergh, Niklas
    Dahlof, Bjorn
    PULMONARY CIRCULATION, 2024, 14 (01)
12345